Targeted therapy that specifically focuses on EGFR has shown significant benefits compared to conventional chemotherapy and radiotherapy treatments in patients with lung malignancies harboring EGFR-activating mutations (2), leading to profound changes in treatment approaches and research strategies for lung cancer (2). Here, EGFR is linked to lung carcinoma.